Bioresorbable stents are back in the spotlight thanks to some significant progress from multiple medtech companies. Eric Secemsky, MD, discussed some of the biggest breakthroughs in this space at CRT 2025.

“Asking about cannabis use should be part of clinicians' workup to understand patients' overall cardiovascular risk, similar to asking about smoking cigarettes,” one researcher said. Additional details will be presented at ACC.25 in Chicago.

AI has already made a massive impact on healthcare, especially in the fields of cardiology and radiology. With the FDA clearing more and more algorithms, this trend is only expected to grow as time goes on.

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

The new document represents the ACC’s first Concise Clinical Guidance; it was designed to be an easy-to-use reference for keeping track of a complicated topic. 

Clinicians are asking the world's medical societies to come together and agree on one acronym for TAVR/TAVI to avoid unnecessary confusion going forward.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.

TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC.